Uveal melanoma is a type of cancer that develops in the middle layer of your eye called the uvea. It can cause symptoms like blurry vision, floaters, or loss of vision. Melanoma is a type of ...
Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.
The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...
The first patient was enrolled in a phase 3 trial and was randomly assigned to receive treatment for non-metastatic uveal melanoma. This type of melanoma forms in the uvea of the eye, or the area of ...
NICE has recommended tebentafusp as an option for treating HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides it ...
Tebentafusp – sold under the brand name Kimmtrak – is the first treatment of its kind for uveal melanoma, which develops from cells in the middle layer of the eye, known as the uvea.
About Uveal Melanoma Uveal melanoma is a rare and aggressive form of melanoma affecting the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare ...
The RP2-202 trial is a Phase 2/3 study assessing RP2 in combination with nivolumab versus nivolumab and ipilimumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback